Trovan Related Published Studies
Well-designed clinical trials possibly related to Trovan (Trovafloxacin)
Methicillin-sensitive Staphylococcus aureus bacteraemia and endocarditis among injection drug users and nonaddicts: host factors, microbiological and serological characteristics. [2008.04]
Other research related to Trovan (Trovafloxacin)
Trovafloxacin, a fluoroquinolone antibiotic with hepatotoxic potential, causes mitochondrial peroxynitrite stress in a mouse model of underlying mitochondrial dysfunction. [2010.10.06]
Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis for experimental murine melioidosis. [2010.07]
Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis against experimental murine Brucella melitensis infection. [2010.07]
Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury. [2009.01]
Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. [2007.11]
Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. [2005.01]
Other possibly related research studies
In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent. [2006.09]
Dog colonoscopy model for predicting human colon absorption. [2006.07]
In vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi Arabia. [2005.01]
Effect of ethanol on fluoroquinolone efficacy in a rat model of pneumococcal pneumonia. [2006.01]
Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia. [2006.04]
Telithromycin: The first ketolide antimicrobial. [2005.08]
Effect of recombinant murine granulocyte colony-stimulating factor with or without fluoroquinolone therapy on mixed-infection abscesses in mice. [2005.09]
Antimicrobial safety: focus on fluoroquinolones. [2005.07.15]
Effect of cirrhosis on antibiotic efficacy in a rat model of pneumococcal pneumonia. [2005.02]
Antimicrobial susceptibility and mechanism of resistance to fluoroquinolones in Staphylococcus intermedius and Staphylococcus schleiferi. [2007.10]
Ocular toxicity of fluoroquinolones. [2007.08]
Knowledge creation about ADRs--turning the perspective from the rear mirror to the projector? [2008.03]
Topoisomerase II inhibition involves characteristic chromosomal expression patterns. [2008.07.08]
Sitafloxacin hydrate for bacterial infections. [2008.07]
Levofloxacin-induced delirium with psychotic features. [2008.07]
Understanding informed consent for participation in international health research. [2009.08]
Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. [2009]
Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. [2009.06.15]
Net efficacy adjusted for risk (NEAR): a simple procedure for measuring risk:benefit balance. [2008]
Clinical ethics in African countries and emerging nurse's role in Nigeria. [2009.12]
Ethical problems in conducting research in acute epidemics: the Pfizer meningitis study in Nigeria as an illustration. [2010.04]
The use of gastrointestinal intubation studies for controlled release development. [2009.09]
Hepatic safety of antibiotics used in primary care. [2011.07]
Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp. [2010.08]
Ethical problems in conducting research in acute epidemics: the Pfizer meningitis
study in Nigeria as an illustration. [2010]
Clinical efficacy of moxifloxacin versus comparator therapies for
community-acquired pneumonia caused by Legionella spp. [2010]
|